HAS GLOBALISATION PEAKED ?

Globalisation has always been a matter of controversy, it has been widely credited with a rise in productivity by exploiting gains of trade.

Highlights:

  • Globalisation has been widely perceived as boon and bane: It is credited with a rise in productivity, higher growth, rising standards of living in EM economies and wider choices for consumers, but also blamed for de-industrialisation in the Western world and rising inequality.
  • Economically, globalisation may have hit a “natural limit” as technology makes wage differentials a less important driver of production off-shoring. Politically, rising inequality has become a ramp for protectionism. Both forces let us to believe that globalisation has peaked. The COVID-19 outbreak will only accelerate the slowbalisation already underway.
  • Protectionism and trade frictions tend to increase political uncertainty, thus enhancing the volatility embedded in the equity risk premium and valuations. Future earnings growth and total returns are expected to be lower than in the last 20 years.
  • Countries with higher participation to the global value chain – EU and EMs – are more exposed to these tectonic shifts. Investors will cherish high growth, patent-protected and technology-oriented stocks.

Download the full publication below

HAS GLOBALISATION PEAKED ?

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
Q3 EARNINGS SEASON STARTS WELL. EXPECT STABILIZATION IN REVISIONS MOMENTUM BUT RECOVERY WILL CONTINUE
The Q3 reporting season has just started. For the US, expectations are for a yearly earnings growth of -21% after -31% in Q2. As for sectors, worse growth rates in the US are expected for energy, industrials and discretionary while pharma, utilities, IT and staples should rank better than the index.